Proteome analysis of the effects of sorafenib on human hepatocellular carcinoma cell line HepG2

Medical Oncology

Volumn 29, Issue 3, 2012, Pages 1827-1836

  Suo, Aili ^a   Zhang, Mingxin ^a   Yao, Yu ^a   Zhang, Lingmin ^a   Huang, Chen ^a,b   Nan, Kejun ^a   Zhang, Wanggang ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Human hepatocellular carcinoma; Proteome; Sorafenib

Indexed keywords

CYCLOPHILIN A; LIPOCORTIN 1; PROTEOME; SORAFENIB;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION; HEP G2 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEOME; TANDEM MASS SPECTROMETRY;

EID: 84872765416     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0013-y     Document Type: Article

References (38)

1. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127(5 suppl 1):S5216.
2. Lai EC, Lau WY. The continuing challenge of hepatic cancer in Asia. Surgeon. 2005;3(3):210-5.
3. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer. 2004;4(5):361-70.
4. Dal Lago L, D'Hondt V, Awada A. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist. 2008;13(8):845-58.
5. Wong SC, Chan CM, Ma BB, Lam MY, Choi GC, et al. Advanced proteomic technologies for cancer biomarker discovery. Expert Rev Proteomics. 2009;6(2):123-34.
6. Wosikowski K, Regis JT, Robey RW, Alvarez M, Buters JT, et al. Normal p53 status and function despite the development of drug resistance in human breast cancer cells. Cell Growth Differ. 1995;6(11):1395-403.
7. Mortz E, Krogh TN, Vorum H, Görg A. Improved silver staining protocols for high sensitivity protein identification using matrixassisted laser desorption/ionization-time of flight analysis. Proteomics. 2001;1(11):1359-63.
8. Andon NL, Hollingworth S, Koller A, Greenland AJ, Yates JR III, et al. Proteomic characterization of wheat amyloplasts using identification of proteins by tandem mass spectrometry. Proteomics. 2002;2(9):1156-68.
9. Yates JR III, Eng JK, McCormack AL, Schieltz D. Method to correlate tandem mass spectra of modified peptides to amino acid sequences in the protein database. Anal Chem. 1995;67(8): 1426-36.
10. Chen HJ, Xiao JR, Yuan W. Loss of p16INK4, alone and with overexpression of osteopontin, correlates with survival of patients with spinal metastasis from hepatocellular carcinoma. Med Oncol. 2010;27(3):1005-9.
11. Wang J, Zhang M, Zhang L, Cai H, Zhou S, et al. Correlation of Nrf2, HO-1, and MRP3 in gallbladder cancer and their relationships to clinicopathologic features and survival. J Surg Res. 2010;164(1):e99-105.
12. Liu L, Cao Y, Chen C, Zhang X, McNabola A, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66(24):11851-8.
13. Yang Y, Liu X, Fang X, Wang X. Proteomic analysis of mitochondria in Raji cells following exposure to radiation: implications for radiotherapy response. Protein Pept Lett. 2009;16(11): 1350-9.
14. Wang W, Goswami S, Lapidus K, Wells AL, Wyckoff JB, et al. Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors. Cancer Res. 2004;64(23):8585-94.
15. Yanagawa T, Iwasa S, Ishii T, Tabuchi K, Yusa H, et al. Peroxiredoxin I expression in oral cancer: a potential new tumor marker. Cancer Lett. 2000;156(1):27-35.
16. Noh DY, Ahn SJ, Lee RA, Kim SW, Park IA, et al. Overexpression of peroxiredoxin in human breast cancer. Anticancer Res. 2001;21(3B):2085-90.
17. Cha MK, Suh KH, Kim IH. Overexpression of peroxiredoxin I and thioredoxin 1 in human breast carcinoma. J Exp Clin Cancer Res. 2009;28:93.
18. Masaki T, Tokuda M, Ohnishi M, Watanabe S, Fujimura T, et al. Enhanced expression of the protein kinase substrate annexin in human hepatocellular carcinoma. Hepatology. 1996;24(1):72-81.
19. Bai XF, Ni XG, Zhao P, Liu SM, Wang HX, et al. Overexpression of annexin 1 in pancreatic cancer and its clinical significance. World J Gastroenterol. 2004;10(10):1466-70.
20. Ahn SH, Sawada H, Ro JY, Nicolson GL. Differential expression of annexin I in human mammary ductal epithelial cells in normal and benign and malignant breast tissues. Clin Exp Metastasis. 1997;15(2):151-6.
21. de Coupade C, Gillet R, Bennoun M, Briand P, Russo-Marie F, et al. Annexin 1 expression and phosphorylation are upregulated during liver regeneration and transformation in antithrombin III SV40 T large antigen transgenic mice. Hepatology. 2000;31(2): 371-80.
22. Campa MJ, Wang MZ, Howard B, Fitzgerald MC, Patz EF Jr. Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin A as potential molecular targets in non-small cell lung. Cancer Res. 2003;63(7):1652-6.
23. Li M, Zhai Q, Bharadwaj U, Wang H, Li F, et al. Cyclophilin A is overexpressed in human pancreatic cancer cells and stimulates cell proliferation through CD147. Cancer. 2006;106(10): 2284-94.
24. Zheng J, Koblinski JE, Dutson LV, Feeney YB, Clevenger CV. Prolyl isomerase cyclophilin A regulation of Janus-activated kinase 2 and the progression of human breast cancer. Cancer Res. 2008;68(19):7769-78.
25. Wong CS, Wong VW, Chan CM, Ma BB, Hui EP, et al. Identification of 5-fluorouracil response proteins in colorectal carcinoma cell line SW480 by two-dimensional electrophoresis and MALDI-TOF mass spectrometry. Oncol Rep. 2008;20(1):89-98.
26. Huang CF, Sun ZJ, Zhao YF, Chen XM, Jia J, et al. Increased expression of peroxiredoxin 6 and cyclophilin A in squamous cell carcinoma of the tongue. Oral Dis. 2011;17(3):328-34.
27. Al-Ghoul M, Brück TB, Lauer-Fields JL, Asirvatham VS, Zapata C, et al. Comparative proteomic analysis of matched primary and metastatic melanoma cell lines. J Proteome Res. 2008;7(9): 4107-18.
28. Lee J. Novel combinational treatment of cisplatin with cyclophilin A inhibitors in human hepatocellular carcinomas. Arch Pharm Res. 2010;33(9):1401-9.
29. Dai Z, Liu YK, Cui JF, Shen HL, Chen J, et al. Identification and analysis of altered alpha1, 6-fucosylated glycoproteins associated with hepatocellular carcinoma metastasis. Proteomics. 2006;6(21):5857-67.
30. Goan YG, Zhou B, Hu E, Mi S, Yen Y. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2, 2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res. 1999;59(17):4204-7.
31. Cao MY, Lee Y, Feng NP, Xiong K, Jin H, et al. Adenovirusmediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma. Clin Cancer Res. 2003;9(12):4553-61.
32. Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res. 2004;64(11):3761-6.
33. Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res. 2004;10(4):1318-25.
34. Phadke MS, Krynetskaia NF, Mishra AK, Krynetskiy E. Glyceraldehyde 3-phosphate dehydrogenase depletion induces cell cycle arrest and resistance to antimetabolites in human carcinoma cell lines. J Pharmacol Exp Ther. 2009;331(1):77-86.
35. Ménasché G, Pastural E, Feldmann J, Certain S, Ersoy F, et al. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat Genet. 2000;25(2):173-6.
36. Wang JS, Wang FB, Zhang QG, Shen ZZ, Shao ZM. Enhanced expression of Rab27A gene by breast cancer cells promoting invasiveness and the metastasis potential by secretion of insulinlike growth factor-II. Mol Cancer Res. 2008;6(3):372-82.
37. Gatenby RA, Gillies RJ. Glycolysis in cancer: a potential target for therapy. Int J Biochem Cell Biol. 2007;39(7-8):1358-66.
38. Fiume L, Vettraino M, Manerba M, Di Stefano G. Inhibition of lactic dehydrogenase as a way to increase the anti-proliferative effect of multi-targeted kinase inhibitors. Pharmacol Res. 2011;63(4):328-34.